Novocure (NVCR) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
July 28, 2016 6:30 AM EDTContinued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016
Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth versus second quarter 2015 and 37 percent growth versus first quarter 2016
Approximately 116 million covered lives in the United States as of June 30, 2016, including an additional 10 million lives placed under coverage during second quarter 2016
National Comprehensive Cancer Network® (NCCN®) published updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers to include Optune as category 2A treatment option for newly diagnosed... More
